Minervax initiates phase I trial with vaccine
Denmark’s Minervax, which is backed by the likes of Novo Seeds and Sunstone Capital, is advancing its vaccine candidate to phase I trials.
BY BENJAMIN WERNER CHRISTENSEN
Up to 310 healthy adult women will now be enrolled in a new phase I study that the Danish-based biotech Minervax is initiating for its vaccine candidate GBS-NN, the company says in a press release.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
